The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors
Open accessAbstract
Synthetic benzamide derivatives were investigated for their ability to inhibit histone deacetylase (HDA). In this study, one of the most active benzamide derivatives, MS-27-275, was examined with regard to its biological properties and antitumor efficacy. MS-27-275 inhibited partially purified human HDA and caused hyperacetylation of nuclear histones in various tumor cell lines. It behaved in a manner similar to other HDA inhibitors, such as sodium butyrate and trichostatin A; MS-27-275 induced p21 WAF1/CIP1 and gelsolin and changed the cell cycle distribution, decrease of S-phase cells, and increase of G 1 -phase cells. The in vitro sensitivity spectrum of MS-27-275 against various human tumor cell lines showed a pattern different than that of a commonly used antitumor agent, 5-fluorouracil, and, of interest, the accumulation of p21 WAF1/CIP1 tended to be faster and greater in the cell lines sensitive to MS-27-275. MS-27-275 administered orally strongly inhibited the growth in seven of eight tumor lines implanted into nude mice, although most of these did not respond to 5-fluorouracil. A structurally analogous compound to MS-27-275 without HDA-inhibiting activity showed neither the biological effects in cell culture nor the in vivo therapeutic efficacy. These results suggest that MS-27-275 acts as an antitumor agent through HDA inhibition and may provide a novel chemotherapeutic strategy for cancers insensitive to traditional antitumor agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, Sr., Chai, Jr., Lu, J., Zhoa, L., Gu, L., & Wang, Z. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
Vogelstein, B. (1992) · Cell · doi:10.1016/0092-8674(92)90421-8 · Cited by 1,862
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Dulić, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J. W., Elledge, S. J., & Reed, S. I. (1994) · Cell · doi:10.1016/0092-8674(94)90379-4 · Cited by 1,465
The retinoblastoma protein is phosphorylated during specific phases of the cell cycle
Buchkovich, K., Duffy, L. A., & Harlow, E. (1989) · Cell · doi:10.1016/0092-8674(89)90508-4 · Cited by 995
Chen, P.-L., Scully, P., Shew, J.-Y., Wang, J. Y. J., & Lee, W.-H. (1989) · Cell · doi:10.1016/0092-8674(89)90517-5 · Cited by 952
Cited by
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Roth, S. Y., Denu, J. M., & Allis, C. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.81 · Cited by 1,845
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Epigenetic therapy of cancer: past, present and future
Yoo, C. B., & Jones, P. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1930 · Cited by 1,289
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
The role of histone deacetylases (HDACs) in human cancer
Ropero, S., & Esteller, M. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.01.001 · Cited by 997
G-quadruplex structures mark human regulatory chromatin
Hänsel-Hertsch, R., Beraldi, D., Lensing, S. V., Marsico, G., Zyner, K., Parry, A., Di Antonio, M., Pike, J., Kimura, H., Narita, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3662 · Cited by 964
Organic Carbamates in Drug Design and Medicinal Chemistry
Ghosh, A. K., & Brindisi, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501371s · Cited by 739
Chang, F., Steelman, L. S., Lee, J. T., Shelton, J. G., Navolanic, P. M., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402945 · Cited by 725
In vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylation
Matsuyama, A., Shimazu, T., Sumida, Y., Saito, A., Yoshimatsu, Y., Seigneurin‐Berny, D., Osada, H., Komatsu, Y., Nishino, N., Khochbin, S., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf682 · Cited by 720
Self-citationHistone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code
THIAGALINGAM, S., CHENG, K., LEE, H. J., MINEVA, N., THIAGALINGAM, A., & PONTE, J. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb05964.x · Cited by 700
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Mottamal, M., Zheng, S., Huang, T., & Wang, G. (2015) · Molecules · doi:10.3390/molecules20033898 · Cited by 680
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
Gallinari, P., Marco, S. D., Jones, P., Pallaoro, M., & Steinkühler, C. (2007) · Cell Research · doi:10.1038/sj.cr.7310149 · Cited by 678
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Alvarez, R., Schiavone, E. M., Ferrara, F., Bresciani, F., et al. (2005) · Nature Medicine · doi:10.1038/nm1161 · Cited by 610
Histone Deacetylase Inhibitors
Miller, T. A., Witter, D. J., & Belvedere, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303094 · Cited by 530
(2003) · PubMed · Cited by 519
Ungerstedt, J. S., Sowa, Y., Xu, W.-S., Shao, Y., Dokmanovic, M., Perez, G., Ngo, L., Holmgren, A., Jiang, X., & Marks, P. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408732102 · Cited by 503
CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS
Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095825 · Cited by 494
(2003) · PubMed · Cited by 465
Nepali, K., Sharma, S., Sharma, M., Bedi, P. M. S., & Dhar, K. L. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.03.018 · Cited by 435
Histone Deacetylase Inhibitors
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91004-4 · Cited by 415
Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., & Horinouchi, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.87 · Cited by 412
Ryan, Q. C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J. B., Ye, J., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.188 · Cited by 411
Sambucetti, L. C., Fischer, D. D., Zabludoff, S., Kwon, P. O., Chamberlin, H., Trogani, N., Xu, H., & Cohen, D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34940 · Cited by 390
Weichert, W., Röske, A., Niesporek, S., Noske, A., Buckendahl, A.-C., Dietel, M., Gekeler, V., Boehm, M., Beckers, T., & Denkert, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0990 · Cited by 361
Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases
Hu, E., Dul, E., Sung, C.-M., Chen, Z., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Liu, R., Lago, A., Hofmann, G., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055541 · Cited by 347
Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues
Choi, J., Kwon, H. J., Yoon, B., Kim, J., Han, S. U., Joo, H. J., & Kim, D. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb02153.x · Cited by 346
Cell-cycle dysregulation and anticancer therapy
Stewart, Z. A., Westfall, M. D., & Pietenpol, J. A. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00026-9 · Cited by 344
Nidhi, Glick, M., Davies, J. W., & Jenkins, J. L. (2006) · Journal of Chemical Information and Modeling · doi:10.1021/ci060003g · Cited by 340
Minetti, G. C., Colussi, C., Adami, R., Serra, C., Mozzetta, C., Parente, V, Fortuni, S., Straino, S., Sampaolesi, M., Di Padova, M., et al. (2006) · Nature Medicine · doi:10.1038/nm1479 · Cited by 339
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
Histone deacetylase inhibitors
Monneret, C. (2005) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.10.001 · Cited by 338
Fournel, M., Bonfils, C., Hou, Y., Yan, P. T., Trachy-Bourget, M.-C., Kalita, A., Liu, J., Lu, A.-H., Zhou, N. Z., Robert, M.-F., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2026 · Cited by 332
Histone deacetylation in epigenetics: An attractive target for anticancer therapy
Mai, A., Massa, S., Rotili, D., Cerbara, I., Valente, S., Pezzi, R., Simeoni, S., & Ragno, R. (2005) · Medicinal Research Reviews · doi:10.1002/med.20024 · Cited by 319
Hu, E., Chen, Z., Fredrickson, T., Zhu, Y., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Sung, C.-M., Liu, R., & Winkler, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m908988199 · Cited by 309
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 308
Ning, Z.-Q., Li, Z.-B., Newman, M. J., Shan, S., Wang, X.-H., Pan, D.-S., Zhang, J., Dong, M., Du, X., & Lu, X.-P. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1766-x · Cited by 303
“5–50 mg/kg dosedependently reduced tumor size and tumor weight, and the dose of 50 mg/kg produced similar or greater efficacy compared with the control drugs 5-fluorouracil (5-FU, 20 mg/kg) and MS-275 (25 mg/kg, which was reported as the maximum tolerated dose in xenograft models [15]).”
BackgroundMethodHe, L.-Z., Tolentino, T., Grayson, P., Zhong, S., Warrell, R. P., Rifkind, R. A., Marks, P. A., Richon, V. M., & Pandolfi, P. P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11537 · Cited by 303
Histone deacetylase inhibitors in cancer treatment
Vigushin, D. M., & Coombes, R. C. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200201000-00001 · Cited by 301
Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives
Suzuki, T., Ando, T., Tsuchiya, K., Fukazawa, N., Saito, A., Mariko, Y., Yamashita, T., & Nakanishi, O. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980565u · Cited by 293
Self-citationFandy, T. E., Herman, J. G., Kerns, P., Jiemjit, A., Sugar, E. A., Choi, S.-H., Yang, A. S., Aucott, T., Dauses, T., Odchimar-Reissig, R., et al. (2009) · Blood · doi:10.1182/blood-2009-02-203547 · Cited by 282
A Fluorogenic Histone Deacetylase Assay Well Suited for High-Throughput Activity Screening
Wegener, D., Wirsching, F., Riester, D., & Schwienhorst, A. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00305-8 · Cited by 282
Gojo, I., Jiemjit, A., Trepel, J. B., Sparreboom, A., Figg, W. D., Rollins, S., Tidwell, M. L., Greer, J., Chung, E. J., Lee, M.-J., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021873 · Cited by 281
Lago, S., Nadai, M., Cernilogar, F. M., Kazerani, M., Domíniguez Moreno, H., Schotta, G., & Richter, S. N. (2021) · Nature Communications · doi:10.1038/s41467-021-24198-2 · Cited by 269
Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides
Bressi, J. C., Jennings, A. J., Skene, R., Wu, Y., Melkus, R., Jong, R. D., O’Connell, S., Grimshaw, C. E., Navre, M., & Gangloff, A. R. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.091 · Cited by 261
Chen, Q., Yang, B., Liu, X., Zhang, X. D., Zhang, L., & Liu, T. (2022) · Theranostics · doi:10.7150/thno.73223 · Cited by 261
Histone deacetylase as a therapeutic target
Krämer, O. H., Göttlicher, M., & Heinzel, T. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00438-6 · Cited by 257
Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10
Guardiola, A. R., & Yao, T.-P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109861200 · Cited by 253
Histone deacetylase inhibitors: from target to clinical trials
Kelly, W. K., O’Connor, O. A., & Marks, P. A. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.12.1695 · Cited by 253
Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
Chou, C. J., Herman, D., & Gottesfeld, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807045200 · Cited by 223
Cloning and characterization of a novel human histone deacetylase, HDAC8
BUGGY, J. J., SIDERIS, M. L., MAK, P., LORIMER, D. D., MCINTOSH, B., & CLARK, J. M. (2000) · Biochemical Journal · doi:10.1042/bj3500199 · Cited by 197
Targeting Class I Histone Deacetylases in a “Complex” Environment
Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.006 · Cited by 180
Jung, M., Brosch, G., Kölle, D., Scherf, H., Gerhäuser, C., & Loidl, P. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm991091h · Cited by 176
Gore, L., Rothenberg, M. L., O'Bryant, C. L., Schultz, M. K., Sandler, A. B., Coffin, D., McCoy, C., Schott, A., Scholz, C., & Eckhardt, S. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1461 · Cited by 171
“MS-275 is unique among HDAC inhibitors in clinical development, in that it inhibits class I HDAC (HDAC 1 and 3) more than class II (HDAC 4), displays a unique in vitro cytotoxicity profile in the NCI COMPARE algorithm, inhibits tumor cell growth in nude mice comparable with or better than conventional cytotoxic agents…”
BackgroundInfluentialInhibition of Histone Deacetylation: A Strategy for Tumor Radiosensitization
Camphausen, K., & Tofilon, P. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6202 · Cited by 162
Kosugi, H., Towatari, M., Hatano, S., Kitamura, K., Kiyoi, H., Kinoshita, T., Tanimoto, M., Murate, T., Kawashima, K., Saito, H., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401508 · Cited by 150
Entinostat: a promising treatment option for patients with advanced breast cancer
Connolly, R. M., Rudek, M. A., & Piekarz, R. (2017) · Future Oncology · doi:10.2217/fon-2016-0526 · Cited by 148
Buggy, J. J., Cao, Z. A., Bass, K. E., Verner, E., Balasubramanian, S., Liu, L., Schultz, B. E., Young, P. R., & Dalrymple, S. A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0442 · Cited by 127
Strategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
Entinostat for treatment of solid tumors and hematologic malignancies
Knipstein, J., & Gore, L. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.613822 · Cited by 110
“Tumor types included were breast, colon, gastrointestinal stromal tumor, melanoma, NSCLC, prostate, adrenocortical carcinoma, carcinoid, Ewing sarcoma, rectal adenocarcinoma, mesothelioma, pancreatic, RCC, sarcoma and leiomyosarcoma.”
BackgroundInfluentialSen, K., Banerjee, S., & Mandal, M. (2019) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2019.04.035 · Cited by 110
Targeting the acetylation signaling pathway in cancer therapy
Dang, F., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.001 · Cited by 109
Ma, K., Qin, L., Matas, E., Duffney, L. J., Liu, A., & Yan, Z. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0073-1 · Cited by 71
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
Batlevi, C. L., Kasamon, Y., Bociek, R. G., Lee, P., Gore, L., Copeland, A., Sorensen, R., Ordentlich, P., Cruickshank, S., Kunkel, L., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.142406 · Cited by 59
Tan, Y., Zhang, S., Zhu, H., Chu, Y., Zhou, H., Liu, D., & Huo, J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.48 · Cited by 35
Ghiboub, M., Elfiky, A. M. I., de Winther, M. P. J., Harker, N. R., Tough, D. F., & de Jonge, W. J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050336 · Cited by 28
Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization
Kattar, S. D., Surdi, L. M., Zabierek, A., Methot, J. L., Middleton, R. E., Hughes, B., Szewczak, A. A., Dahlberg, W. K., Kral, A. M., Ozerova, N., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.083 · Cited by 29
Class I HDAC inhibition is a novel pathway for regulating astrocytic apoE secretion
Dresselhaus, E., Duerr, J. M., Vincent, F., Sylvain, E. K., Beyna, M., Lanyon, L. F., LaChapelle, E., Pettersson, M., Bales, K. R., & Ramaswamy, G. (2018) · PLOS ONE · doi:10.1371/journal.pone.0194661 · Cited by 25
HDAC1 governs iron homeostasis independent of histone deacetylation in iron-overload murine models
Yin, X., Wu, Q., Monga, J., Xie, E., Wang, H., Wang, S., Zhang, H., Wang, Z.-Y., Zhou, T., Shi, Y., et al. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7161 · Cited by 22
Metadata
- Authors
- Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-04-13
- Volume
- 96
- Issue
- 8
- Pages
- 4592-4597
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2082739830
- Cited by
- 694
- References
- 46
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.